Organisation paid for research Program year 2025 Source: CMS Open Payments

Investigate MD LLC

Neither a doctor nor a teaching hospital

Research payments

$3,308,233

310 payments

Through program year 2025, Investigate MD LLC is reported as receiving $3,308,233 in research payments, across 310 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$577,313	31
2024	Research	$56,673	23
2023	Research	$256,498	57
2022	Research	$1,079,018	60
2021	Research	$309,165	51
2020	Research	$518,713	58
2019	Research	$510,853	30

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $1,766,010 140 payments
Allergan Inc. $1,221,602 86 payments
Endo Pharmaceuticals Inc. $133,931 21 payments
Galderma Laboratories, L.P. $104,995 11 payments
Arcutis Biotherapeutics, Inc. $26,019 17 payments
Kiniksa Pharmaceuticals, Ltd. $21,657 25 payments
Eli Lilly and Company $11,333 2 payments
Horizon Therapeutics plc $8,500 1 payment
Sanofi US Services Inc. $6,500 2 payments
LEO Pharma AS $3,808 2 payments

Studies the money was for Research payments · program years 2019–2025

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Na??ve Adult Participants With Glabellar Lines $670,423 9 payments
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) $386,241 6 payments
Ph 3 Open-label Extension Study $178,906 12 payments
PH 3 Pivotal LCL and GL and LCL - Useu $177,420 10 payments
Ph 3 Pivotal GL Only - US/EU $167,333 13 payments
Ph 3 Pivotal LCL and GL LCL - USEU $165,966 6 payments
Ph 3 Open-label Extension Study $163,654 10 payments
Ph 3 Pivotal LCL and GL+ LCL - US/EU $148,119 13 payments
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naive Adult Participants With Glabellar Lines $134,676 4 payments
Ph 3 Pivotal GL Only - USEU $120,799 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.